From Hope to Reality: How Smart Drugs Are Changing the Future of Fertility Medications

Global fertility drugs market is anticipated to grow at a considerable CAGR of around 6.1% during the forecast period (2024-2031). This growth can be largely attributed to the rising levels of infertility, as well as the enhanced awareness and acceptance of fertility treatments in modern societies. New and advanced fertility drug formulations besides the improved method of drug delivery improve the quality of treatment while minimizing the side effects, hence expanding the market. Further, the increasing delay in having children in developed nations and better healthcare facilities in developing countries is also expanding the market growth. The market players are adopting several methods such as funding, partnerships, mergers and acquisitions, and new product launches to stay competitive in the market which significantly contributes to the market growth. 

Browse the full report description of “Fertility Drug Market Size, Share & Trends Analysis Report by Gender Type (Female Fertility Treatment, and Male Fertility Treatment), by Treatment Type (Hormonal, In Vitro Fertilization (IVF), Intra Cytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and Alternative and Complementary Treatment), and by Infertility Type (Problem with Ovulating, Unexplained Infertility, Blocked or Damaged Tubes, Endometriosis, and Polycystic Ovarian Syndrome) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/fertility-drugs-market

Recent Market Developments

• In March 2024, Future Generali India Insurance launched Health PowHER, a product developed specifically for women's healthcare at different periods of their lives. The product will provide several therapies, one of which will be an infertility treatment. 

• In February 2024, Lupin, a global pharmaceutical giant introduced Ganirelix Acetate Injection. This prefilled syringe with a single dose is meant to prevent women who have ovarian hyperstimulation from experiencing early surges in luteinizing hormone (LH).

• In June 2022, Mankind Pharma developed and launched a generic version of Dydrogestrone tablets for the treatment of patients’ pregnancy-related complications in India. This drug was an equivalent version of Abbott Duphaston tablets. 

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered-

o By Gender Type

o By Treatment Type 

o By Infertility Type

• Regions Covered-

o North America 

o Europe 

o Asia-Pacific 

o Rest of the World 

• Competitive Landscape - Bayer AG, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson Services, Inc., and Novartis AG. among others.

The key question addressed by the Report

• What is the market growth rate? 
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Fertility Drug Market Report Segment

By Gender Type

• Female Fertility Treatment
• Male Fertility Treatment

By Treatment Type

• Hormonal 
• In Vitro Fertilization (IVF)
• Intra Cytoplasmic Sperm Injection (ICSI)
• Intrauterine Insemination (IUI)
• Alternative and Complementary Treatment

By Infertility Type

• Problem with Ovulating
• Unexplained Infertility
• Blocked or Damaged Tubes
• Endometriosis
• Polycystic Ovarian Syndrome 

Global Fertility Drug Market Reports Segmented By Region

North America 

• United States

• Canada

Europe 

• UK

• Italy

• Spain

• Germany

• France

• Rest of Europe

Asia-Pacific 

• India

• China

• Japan

• South Korea

• Rest of Asia-Pacific

Rest of the World 

• Middle East & Africa

• Latin America

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/fertility-drugs-market